Lung Program


With annual treatment costs estimated in the billions, lung disease is the third-leading cause of death in the United States. The mission in the Lung Program at the Cedars-Sinai Regenerative Medicine Institute is to use lung stem cells to identify critical determinants of lung epithelial maintenance, renewal and remodeling that can lead to more effective therapies for lung diseases.


The Lung Program focuses on fibroproliferative lung diseases—idiopathic pulmonary fibrosis (IPF) and bronchiolitis obliterans syndrome (BOS). For these lung diseases, the mechanism of disease inhalation and progression are poorly understood, and prognosis is poor due to the lack of effective treatment options. End-stage IPF and BOS are characterized by dysfunctional epithelium, coupled with expansion of underlying mesenchyme and deposition of extra cellular matrix leading to respiratory failure.


Barry Stripp, PhD
Collaborative Research

Cross section of a conducting airway from a mouse lung outlining some of the different cells that make up the normal lung.

Overall view of the lung with alveolar cells marked in red and conducting airways outlined in green.

Lineage tracing of airway epithelial progenitor cells with Trp53 loss-of-function using a multicolored Confetti reporter to follow cellular responses to ionizing radiation.

Have Questions or Need Help?

Contact us if you have questions, or wish to learn more about the Board of Governors Regenerative Medicine Institute.

Board of Governors Regenerative Medicine Institute
Pavilion, Eighth Floor
8700 Beverly Blvd.
Los Angeles, CA 90048

Fax: 310-248-8066